trending Market Intelligence /marketintelligence/en/news-insights/trending/clznuhotzrqvluisxtqwpq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Trillium skin cancer treatment receives US FDA's orphan drug status

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Trillium skin cancer treatment receives US FDA's orphan drug status

Trillium Therapeutics Inc. said its skin cancer treatment TTI-621 received the U.S. Food and Drug Administration's orphan drug designation.

The drug, being studied as a treatment for cutaneous T cell lymphoma, works by activating the patient's immune system after blocking the activity of CD47, a protein commonly found on the surface of cancer cells.

Cutaneous T cell lymphoma is a rare type of cancer that begins in the white blood cells and attacks the skin.

The orphan drug status will help expedite development of the Toronto-based company's drug. Once approved, the treatment will be eligible for seven years of market exclusivity.